Glucagon-like peptide 1, as a stimulator for glucose-dependent insulin secretion that is involved in the regulation of satiety, the inhibition of food intake, and the promotion of body weight loss, was found in higher levels in persons with schizophrenia treated with antipsychotics compared with their healthy controls [75], and it was associated with insulin resistance, obesity, and metabolic syndrome [76]. This evidence concerns the gene GCG and schizophrenia.